Detalhe da pesquisa
1.
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Ann Oncol
; 35(2): 200-210, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37956738
2.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Ann Oncol
; 35(1): 107-117, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871702
3.
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Ann Oncol
; 35(1): 98-106, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871701
4.
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
Ann Oncol
; 35(4): 392-401, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244927
5.
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Ann Oncol
; 34(11): 1047-1054, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37678672
6.
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Ann Oncol
; 34(4): 389-396, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709039
7.
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Ann Oncol
; 33(4): 434-444, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35066105
8.
French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).
Prog Urol
; 32(15): 1102-1140, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400479
9.
French AFU Cancer Committee Guidelines - Update 2022-2024: Muscle-Invasive Bladder Cancer (MIBC).
Prog Urol
; 32(15): 1141-1163, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400480
10.
French AFU Cancer Committee Guidelines - Update 2022-2024: Upper urinary tract urothelial cancer (UTUC).
Prog Urol
; 32(15): 1164-1194, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400481
11.
[Guidelines from the cancer (CC-AFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG]. / Recommandations des Comités de cancérologie (CC-AFU) et d'infectiologie (CI-AFU) de l'Association française d'urologie pour la prise en charge effets indésirables et complications du BCG.
Prog Urol
; 32(3): 165-176, 2022 Mar.
Artigo
em Francês
| MEDLINE | ID: mdl-35125314
12.
[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer]. / Recommandations du Comité de cancérologie de l'Association Française d'Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d'épirubicine et de BCG pour le traitement des tumeurs de la vessie n'infiltrant pas le muscle (TVNIM).
Prog Urol
; 32(5): 299-311, 2022 Apr.
Artigo
em Francês
| MEDLINE | ID: mdl-35151545
13.
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
Ann Oncol
; 32(11): 1381-1390, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416362
14.
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
BMC Cancer
; 21(1): 593, 2021 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34030643
15.
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Ann Oncol
; 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38490358
16.
FIGHT against FGF/FGFR alterations: what are the next steps?
Ann Oncol
; 33(5): 460-462, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35450697
17.
Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Ann Oncol
; 28(3): 576-582, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993806
18.
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 33(3): 244-258, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861372
19.
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
Ann Oncol
; 28(12): 3044-3050, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950298
20.
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
Ann Oncol
; 28(10): 2481-2488, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961845